BCR/ABL and leukemia

Leukemia Research

Volumn 20, Issue 6, 1996, Pages 523-529

  Butturini, Anna ^a   Arlinghaus, Ralph B ^b   Gale, Robert Peter ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Salick Health Care Inc   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukemia; Oncogenes; Ph1 chromosome

Indexed keywords

BCR ABL PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR BIOLOGY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030176261     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00057-7     Document Type: Article

References (87)

1. 1. Kurzrock R., Gutterman J. U. & Talpaz M. (1988) The molecular genetics of Philadelphia chromosome positive leukemias. N. Engl. J. Med. 319, 990.
2. 2. Shtivelman F., Ufshitz B., Gale R. P., et al. (1985) Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 315, 550.
3. 3. Heisterkamp N., Stam K., Groffen J., et al. (1985) Structural organization of the BCR gene and its role in the Ph translocation. Nature 314, 758.
4. 4. Kurzrock R., Shtalrid M., Romero P., et al. (1987) A novel c-ABL protein product in Philadelphia positive acute lymphoblastic leukemia. Nature 325, 631.
5. 5. Chan L. L., Karhi K. K., Rayter S. I., et al. (1987) A novel ABL protein expressed in Philadelphia positive acute lymphoblastic leukemia. Nature 325, 635.
6. 6. Pendergast A. M., Muller A. J., Havlik M. H., Muro J. & Witte O. N. (1991) BCR sequences essential for transformation by the BCR/ABL oncogene bind to the ABL SH2 regulatory domain in a nonphosphotyrosine-dependent manner. Cell 66, 161.
7. 7. Cicchetti P., Mayer B. J., Thiel G. & Baltimore D. (1992) Identification of a protein that binds to the SH3 region of ABL and is similar to BCR and GAP-Rho. Science 257, 803.
8. 8. Kipreos E. T. & Wang J. Y. J. (1992) Cell cycle regulated binding of c-ABL tyrosine kinase to DNA. Science 256, 382.
9. 9. McWhirter J. R. & Wang J. Y. J. (1993) An actin binding function contributes to transformation by the BCR/ABL oncoprotein of Philadelphia chromosome positive human leukemias. EMBO J. 12, 1533.
10. 10. McWhirter J. R., Galasso D. L. & Wary J. Y. J. (1993) A coiled-coil oligermized domain of BCR is essential for the tranformation function of BCR/ABL oncoproteins. Mol. Cell. Biol. 13, 7587.
11. 11. Maru Y., Afar D. E. H., Witte O. N. & Shibuya M. (1994) Tetramer structure is required for BCR\ABL-mediated growth factor independence. Blood 84 (Suppl 1), 514a.
12. 12. Muller A. J., Young J. C., Pendergast A. M., Pandel M., Littman D. R. & Witte O. N. (1991) BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome positive human leukemias. Mol. Cell. Biol. 11, 1785.
13. BCR on tyrosine predominantly at the first BCR exon. Oncogene 8, 101.
14. BCR\ABL is required for transformation but not growth factor independence. Mol. Cell. Biol. 13, 1728.
15. BCR/ABL Blood 82, 1257.
16. BCR and ph-P53. Oncogene 5, 773.
17. 17. Puil L., Liu J., Gish G., et al (1994) BCR-ABL oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13, 764.
18. 18. Wetzler M., Talpaz M., Van Etten R. A., Hirsh-Ginsberg C., Beran M. & Kurzrock R. (1993) Subcellular localization of BCR, ABL, and BCR/ABL proteins in normal and leukemic cells and correlation with myeloid differentiation. J. Clin. Invest. 92, 1925.
19. 19. Pendergast A. M., Quilliam L. A., Cripe L. D., et al. (1993) BCR/ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175.
20. BCR/ABL transformation of murine myeloid cells. Blood 82, 1838.
21. 21. Druker B., Ojuda O., Matulonis U., Saglia R., Roberts T. & Griffin J. D. (1992) Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 79, 2215.
22. BCR/ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3′-kinase. Leukemia 8, 115.
23. 23. ten Hoeve J., Arlinghaus R. B., Guo J. Q., Heisterkamp N. & Groffen J. (1994) Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84, 1731.
24. 24. ten Hoeve J., Kaartinen V., Fioretos T., Haataja L., Voncken J. W., Heisterkamp N. & Groffen J. (1994) Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res. 54, 2563.
25. 25. Nichols G. L., Raines M. A., Vera J. C., Laconis L., Tempst P. & Golde D. W. (1994) Identification of CRKL as the constitutively phosphorylated 39KD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84, 2912.
26. 26. Sawyers C. L., Callahan W. A. & Witte O. N. (1992) Dominant negative Myc blocks transformation by ABL oncogenes. Cell 70, 901.
27. 27. Afar D. E., Goga A., McLaughin J., Witte O. N. & Sawyers C. L. (1994) Differential complementation of BCR/ABL point mutants with c-Myc. Science 264, 4244.
28. V-ABL induce an increase in the tyrosine phosphorylation of P93c-Fes. J. Biol. Chem. 269, 5764.
29. BCR/ABL confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Leukemia 8, 1257.
30. 30. Salgia R., Li J. L., Lo S. H., et al. (1994) Molecular cloning of paxillin, a focal adhesion phosphoprotein involved in a growth factor receptor and oncogene signal transduction in hematopoietic cells. Blood 84 (Suppl 1), 1484a.
31. 31. Van Etten R. A., Jackson P. & Baltimore D. (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58, 669.
32. 32. Sawyers C. L., McLaughlin J., Goga A., Havlik M. & Witte O. (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77, 121.
33. 33. Shore S. K., La Cava M., Yendapalli S. & Reddy E. P. (1994) Structural alterations in the carboxyterminal domain of the BCR/ABL gene product activate its fibroblastic tranformin potential. J. Biol. Chem. 269, 5413.
34. 34. Renshaw M. W., Kipreos E. T., Albrecht M. R. & Wang J. Y. J. (1992) Oncogene v-abl can inhibit or stimulate growth depending on the cell context. EMBO J. 11, 3941.
35. 35. Mandanas R. A., Boswell H. S., Lu L. & Leibowitz D. (1992) BCR/ABL confers factor independence upon a murine myeloid cell line. Leukemia 6, 796.
36. 36. Sirard C., Laneuville P. & Dick J. E. (1994) Expression of BCR/ABL abrogates factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanism. Blood 83, 1575.
37. BCR/ABL tyrosine kinase on proliferation of a growth factor dependent murine myeloid cell line. Oncogens 9, 149.
38. 38. Ilaria R. L. & van Etten R. A. (1994) The SH2 domain of P210 BCR/ABL is not required for transformation of hematopoietic growth factor-dependent cell lines. Blood 84, (Suppl 1), 513a.
39. 39. Evans C. A., Owen-Linen P. J., Whetton A. D. & Dive C. (1993) Activation of the Abelson tyrosine kinase activity is associated with apoptosis in hematopoietic cells. Cancer Res. 53, 1735.
40. 40. McGahon A., Bissonette R., Schmitt M., Cotter K. M., Green D. R. & Cotter T. G. (1994) BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179.
41. 41. McLaughin J., Chianese E. & Witte O. N. (1987) In vitro transformation of immature hematopoietic cells by the BCR/ABL oncogene product of Philadelphia chromosome. Proc. Natl. Acad. U.S.A. 84, 6558.
42. 42. Scherle P. A., Dorshkind K. & Witte. O. N. (1990) Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc. Natl. Acad. Sci. U.S.A. 87, 1908.
43. 43. Daley G. Q., van Etten R. A. & Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome. Science 247, 824.
44. 44. Gishizky M. L., Johnson-White J. & Witte O. N. (1993) Efficient transplantation of BCR/ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 90, 3755.
45. 45. Gishizky M. L., Johnson-White J. & Witte O. N. (1993) Evalutating the effect of P210 BCR/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia. Sem. Hematol. 30 (Suppl 3), 6.
46. 46. Elefanty A. G. & Cory S. (1992) Hematologic disease induced in BALB\c mice by a BCR/ABL retrovirus is influenced by the infection conditions. Mol. Cell. Biol. 12, 1755.
47. 47. Daley G. Q., van Etten R. A. & Baltimore D. (1991) Blast crisis in a murine model of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U.S.A. 88, 11335.
48. 48. Kelliher M., Knott A., McLaughlin J., Witte O. N. & Rosenberg N. (1991) Differences in oncogenic potency but not target cell specificity distinguish the two forms of BCR/ABL oncogene. Mol. Cell. Biol. 11, 4710.
49. 49. Heisterkamp N., Jenster G., ten-Hoeve J., Zovich D., Pattengale P. K. & Groffen J. (1990) Acute leukemia in BCR/ABL transgenic mice. Nature 344, 251.
50. 50. Groffen J., Voncken J. W., van Schaick H. & Heisterkamp N. (1992) Animal models for chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia 6 (Suppl 1), 44.
51. 51. Vonken J. W., Morris C., Pattengale P. K., Dennert G., Kikly C., Groffen J. & Heisterkamp N. (1992) Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood 79, 1029.
52. 52. Vonken J. W., Griffiths S., Greaves M. F., Pattengale P. K., Heisterkamp N. & Groffen J. (1992) Restricted oncogenity of BCR/ABL P190 in transgenic mice. Cancer Res. 52, 4534.
53. 53. Heisterkamp N., Jenster G., Kioussis D., Pattengale P. K. & Groffen J. (1991) Human BCR/ABL gene has a lethal effect on embryogenesis. Transgenic Res. 1, 45.
54. 54. Fialkow P. J., Jacobson R. T. & Papayannopoulou T. (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, platelet and monocyte macrophage. Am. J. Med. 63, 125.
55. 55. Tachibana N., Raimondi S. C., Lauer S. S., Sartain P. & Dow L. W. (1987) Evidence for a multipotential stem cell disease in soma childhood Philadelphia positive acute lymphoblastic leukemia. Blood 70, 1458.
56. 56. Turhan A. G., Eaves C. J., Kalousek D. K., Eaves A. C. & Humphries R. K. (1988) Molecular analysis of clonality and BCR rearrangements in Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 71, 1495.
57. BCR/ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 53, 3289.
58. 58. Keating A., Wang X. H. & Laraya P. (1994) Variable transcription of BCR/ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 83, 1744.
59. 59. Bedi A., Zehnbauer B. A., Collector M. I., et al. (1993) BCR/ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81, 2898.
60. 60. Stewart M. J., Cox G., Reifel-Miller A., Kim S. Y., Westbrook C. A. & Leibowitz D. S. (1994) A novel transcriptional suppressor located within a downstream intron of the BCR gene. J. Biol. Chem. 269, 10820.
61. 61. Selleri L., van Lindern M., Hermans A., Meijer D., Torelli G. & Grosveld G. (1990) Chronic myeloid leukemia may be associated with several BCR/ABL transcripts including the acute lymphoid leukemia type 7Kb transcript. Blood 75, 1146.
62. 62. Guo J. Q., Hirsch-Ginsberg C. F., Xian Y. M., et al. (1993) Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia. Hemat. Pathol. 7, 91.
63. 63. Morris S. W., Daniel L., Ahmed C. M. L, Elias A. & Lebowitz P. (1990) Relationship of BCR breakpoint to chronic phase duration, survival and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 75, 2035.
64. 64. Dreazen O., Berman M. & Gale R. P. (1988) Molecular abnormalities of BCR and ABL in chronic myelogenous leukemia associated with a long chronic phase. Blood 71, 797.
65. 65. Ben-Yehuda D., Zion M., Avraham A., Krichevsky S. & Ben-Neriah Y. (1994) De novo methylation at the BCR/ABL locus in the course of CML. A possible marker for tumor progression. Blood 84 (Suppl 1), 154a.
66. 66. Konopka J. B., Clark S., McLaughlin J., et al. (1986) Variable expression of the translocated c-abl oncogene in Philadelphia chromosome positive B lymphoid cell lines from chronic myeloid leukemia patients. Proc. Natl. Acad. Sci. U.SA. 83, 4049.
67. 67. Andrews D. F. & Collins S. J. (1987) Heterogeneity in expression of the BCR/ABL fusion transcript in CML blast crisis. Leukemia 1, 718.
68. 68. Mahnen T., Palotie A., Pakkala S., Peltonen L., Ruutu T. & Jansson S. E. (1991) Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 77, 2435.
69. 69. Nelkin B. D., Przepiorka D., Burke P. J., Thomas E. D. & Baylin S. B. (1991) Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood 77, 2431.
70. 70. Wada C, Shionola S., Fujino Y., et al. (1994) Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83, 3449.
71. 71. Kantarjian H. M., Dixon D., Keating M. J., et al. Characteristics of accelerated disease in chronic myeclogenous leukemia. Cancer 61, 1441.
72. 72. Feinstein G., Cimino R., Gale P., et al. (1991) P53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. U.S.A. 88, 6293.
73. 73. Neubauer A., He M., Schmidt C. A., Huhn D. & Liu E. T. (1993) Genetic alteration in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 7, 593.
74. 74. Le Maistre A., Lee M. S., Talpaz M., et al. (1989) Ras oncogene mutations are rare late stage events in chronic myeloid leukemia. Blood 73, 889.
75. 75. McCarthy D. M., Rassool F. V., Goldman J. M., Graham S. V. & Birnie G. D. (1984) Genomic alteration involving the c-myc protooncogene locus during evolution of a case of chronic granulocytic leukemia. Lancet 2, 1362.
76. 76. Mitani K., Ogawa S., Tanaka T., et al. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13, 504.
77. 77. Verfaule C., Miller W., Kay N. & McGlave P. (1989) Adherent lymphokine activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood 74, 793.
78. 78. Verfaille C., Kay N. & McGlave P. (1990) Diminished ALAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 76, 401.
79. 79. Wetzler M., Kurzrock R., Lowe D. G., Kantarjian H., Gutterman J. U. & Talpaz M. (1991) Alteration in bone marrow adherent layer growth factor expression: a novel mechanisms of chronic myelogenous leukemia progression. Blood 78, 2400.
80. 80. Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M. & Gutterman J. U. (1991) Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients. Ann. Intern. Med. 114, 532.
81. 81. Gale R. P., Baccarani M., Horowitz M. M. & Zhang M. J. (1994) Is the course of chronic myelogenous leukemia affected by bone marrow transplantation. An analysis in patients relapsed after bone marrow transplant. Blood 82 (Suppl. 1), 167a.
82. 82. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alpha-2 as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820.
83. 83. Snyder D. S., Wu Y. Wang J. L., et al. (1993) Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82, 600.
84. 84. Pachuk C. J., Yoon K., Moelling K., et al. (1994) Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res. 22, 301.
85. 85. Anafi M, Gazit A., Zehavi A., et al. (1993) Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82, 3524.
86. 86. van Denderen J., ten Hacken P., Berendes P., et al. (1992) Antibody recognition of the tumor-specific b3-2a junction of BCR-ABL chimeric proteins in Philadelphia-chromosome-positive leukemias. Leukemia 6, 1107.
87. 87. Gale R. P., Horowitz M. M., Ash R. C., et al. (1994) Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 120, 646.